Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 35Leukemia 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma 27Lymphoma, Non-Hodgkin 22Burkitt Lymphoma 21Lymphoma, Mantle-Cell 20Leukemia, Lymphocytic, Chronic, B-Cell 20Lymphoma, Large B-Cell, Diffuse 19Lymphoma, Follicular 19Neuroblastoma 18Myelodysplastic Syndromes 18Multiple Myeloma 18Lymphoma, Large-Cell, Immunoblastic 17Lymphoma, B-Cell, Marginal Zone 17Hodgkin Disease 15Astrocytoma 14Medulloblastoma 13Breast Neoplasms 13Recurrence 12Central Nervous System Neoplasms 12Sarcoma 11Myeloproliferative Disorders 10Leukemia, Myeloid, Chronic-Phase 10Ovarian Neoplasms 9Leukemia, Myeloid, Accelerated Phase 9Familial ependymoma 9Carcinoma, Ovarian Epithelial 9Blast Crisis 9Optic Nerve Glioma 8

Interventions

venetoclax 6Azacitidine 6Cytarabine 5fludarabine 4Methotrexate 3fludarabine phosphate 2aldesleukin 2RO6839921 2Mitoxantrone 2Interleukin-2 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Decitabine 2Dasatinib 2zileuton 1thymoglobulin 1spartalizumab 1sabatolimab 1quizartinib 1pulrodemstat besilate 1posaconazole 1plerixafor 1gilteritinib 1etoposide phosphate 1emvododstat 1daratumumab 1blinatumomab 1Sorafenib 1Sirolimus 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myeloid × Filgrastim × Clear all
NCT00943943 2017-03-29

Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

M.D. Anderson Cancer Center

Phase 1 Completed
33 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡